Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Cerevel Therapeutics Holdings Inc's Competitiveness

A competitive positioning analysis and financial ratio benchmarking of Cerevel Therapeutics Holdings Inc (CERE) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q1 2024
Competitors Tracked
113
Publicly traded peers
Peer Group Market Share
-
Share of combined sales, Q1 2024
Revenue Growth Y/Y
-
Peers: -5.67 %
Net Margin
-
Peers: 6.01 %

Key Findings: Cerevel Therapeutics Holdings Inc vs Its Competitors

  • Peer differentiation: Revenue per employee of $0.00M compares with $0.72M for the peer group (0.0x).

Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).

API endpoints for this dataset
https://api.csimarket.com/api/v1/companies/CERE/competitors
https://api.csimarket.com/api/v1/companies/CERE/relationships
https://api.csimarket.com/api/v1/companies/CERE/similar
Programmatic access for models, analytics, and integration workflows.

Cerevel Therapeutics Holdings Inc's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity Profitable Expanding Above Industry Growth Distressed
Cerevel Therapeutics Holdings Inc - - - Yes
Competitors combined (111) 39% 59% 45% 45%
High-Confidence Competitors (2) 50% 50% 50% 50%

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

CERE Stock Performance relative to its Competitors

CERE Competitors (weighted) Percent change over the selected range

Cerevel Therapeutics Holdings Inc's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.
37.7%beat U.S.A. 500
Competitors Combined
(29 of 77)
50%beat U.S.A. 500
High-Confidence
(1 of 2)
Entity TTM Share Price Return
(group: median)
vs U.S.A. 500
Cerevel Therapeutics Holdings Inc - -
Competitors combined (77) 40.4% 63.2%
High-Confidence Competitors (2) 40.4% 63.2%
Similar-Size Competitors (0) 40.4% 63.2%
Similar Growth & Profitability (0) 40.4% 63.2%
Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Cerevel Therapeutics Holdings Inc's competitor groups requires a Commercial License.

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

CERE Stock Performance relative to High-Confidence Competitors

CERE High-Confidence Competitors (equal-weighted, 2) Percent change over the selected range

5 Best-Performing Tracked Competitors, Trailing 12 Months

#CompetitorTTM Share Price Returnvs U.S.A. 500
1 Ventyx Biosciences Inc 282.9% Outperformed
2 Climb Bio Inc 282.9% Outperformed
3 Damora Therapeutics Inc 282.9% Outperformed
4 Praxis Precision Medicines Inc 282.9% Outperformed
5 Gossamer Bio Inc 282.9% Outperformed
Best-Performing Competitor Returns

TTM share price return and U.S.A. 500 outperformance for Cerevel Therapeutics Holdings Inc's best-performing tracked competitors requires a Commercial License.

Source: CSIMarket API, trailing 12 months.

Cerevel Therapeutics Holdings Inc's Comment on Competition and Industry Peers

We believe that we possess a number of competitive strengths that position us to become a leading provider of seeds, traits and bioinformatics technologies, including:

Current Commercial Products with Multiple Advanced Products in Pipeline

Our current commercial products and product pipeline contain numerous traits and seed products with potential across multiple crops including sorghum, sugarcane and corn, among others. Moreover, we are focused on crops and traits outside the primary market areas of major international agrochemical and agricultural biotechnology corporations.

Leading Platform with Full Agricultural Biotech Seed Company Capabilities

We are an agricultural biotechnology company that uses biotechnology, advanced plant breeding and genomic technologies to create high value traits and seeds to produce agricultural crops. Our integrated technology platform delivers a combination of valuable genetic assets and competencies in genomics and gene mapping, biotechnology and bioinformatics. Our iCODE technology enables high throughput genetic testing that can speed up the trait development process. In addition to possessing the research and development capabilities necessary to generate new product candidates, we are vertically integrated, which gives us the ability to bring agricultural biotechnology products to market in select crops.

Extensive Intellectual Property Portfolio of High Value Traits and Germplasm

We have an extensive intellectual property portfolio of both field-validated high value traits and germplasm, which includes thousands of specimens and breeding lines, as well as multiple pools of regionally adapted germplasm spanning multiple climates. We have extensive filings around unique combinations of gene promotors and protein coding sequences. Having both germplasm and field-validated trait portfolios allows us to leverage the synergies created to facilitate innovation in a way that is not possible with germplasm or traits alone. In our focus geographies, we believe that we have a significant advantage over new entrants who would need several generations of germplasm development and/or access to biotech traits to achieve performance equivalent to our current product portfolio and pipeline.

Multiple Out-Licensing Opportunities

Our biotech traits and core technology platforms provide multiple opportunities for exclusive or non-exclusive out-licensing, by crop and/or geography and market. Traits developed through biotechnology, also known as genetic engineering, can be added to multiple crops with similar effect in most cases. Our strategy is to focus on genes that have shown large, step increases in performance and whose benefits are largely maintained across multiple species.

Positioned to Capitalize on Growth of Large End Markets

Our biotechnology platform, which has proven to increase biomass productivity, raise quality, reduce crop inputs and improve cultivation on marginal land, has broad application across multiple end markets and crops. Faced with increasing demand and limited supply in addition to stresses from climate variability and competition for water resources, growers are seeking to improve crop productivity through a number of technologies. Agricultural biotechnology has and will continue to represent a significant source of innovation for increasing crop yields through improving performance of seeds.

Validated, Robust Bioinformatics Platform

We have established our Persephone bioinformatics software as a preeminent platform for storing, organizing, accessing and visualizing genetic information, and have displaced incumbent solutions at major life science companies. The software includes a number of proprietary data management optimizations to quickly access and visualize very large datasets. This speed enables more dynamic visualizations, intuitive discovery and greater insights into genetic information. We believe that our direct experience using Persephone internally and our ability to continually develop and launch new versions with additional features and functions will enable us to further establish our market position in the plant sciences and expand into new markets, such as biomedical research and diagnostics.

Attractive Business Model

Seed businesses traditionally incur significant research and development expenditures and have long product development time lines, but benefit from a combination of high gross margins, low capital expenditure requirements and intellectual property protection. Once developed, seeds require little physical infrastructure or production cost to be replicated for sale. Seeds are typically priced, however, based on a share of the value created to the customer as opposed to their cost of production. In general, seed costs to growers are a relatively small percentage of their total production cost, but the performance of those seeds is critical to the growers’ economics. We believe we can position our business to take advantage of low production costs relative to the high value of our products to our customers.

Management Team with Significant Industry Experience

Our management team includes leading scientists and industry experts who have extensive experience in the field of agricultural biotechnology and possess a deep understanding of a variety of agricultural and biotechnology businesses, including the seed industry.

The seed, agricultural biotechnology and genomics industries are rapidly evolving and new competitors with competing technologies and products are regularly entering the market. We expect to compete with other providers of seed and vegetative propagation materials in the market for our crops as well as other developers of biotech traits, genetic technologies and bioinformatics software. Based on our experience with customers, we believe the primary competitive factors in the seed industry are yield, product quality, performance, scale, price, reliable supply and sustainability. We believe that the competitive factors affecting the market for our Persephone software include product functionality and features, performance, price, ease of product implementation and quality of customer support services. We believe that our products and services currently compete favorably with respect to such factors. However, we may not be able to maintain our competitive position against current and potential competitors.

In the seed industry, our principal competitors may include major international agrochemical and agricultural biotechnology corporations, such as Advanta India Limited, The Dow Chemical Company, Monsanto Company, Pioneer Hi-Bred (DuPont), KWS Saat AG and Syngenta AG, all of which have substantially greater resources to dedicate to research and development, production or marketing than we have and some of which are selling competitive products in our markets. We also face direct competition from other seed companies, such as Chromatin, Inc., S&W Seed Company and Winfield Solutions LLC, a subsidiary of Land O’ Lakes, as well as biotechnology companies, and from academic and government research institutions. In the genomics and bioinformatics market, we face direct competition from academic and government-funded research institutions as well as commercial software developers. In addition, well established companies, such as Illumina, Inc., F.Hoffmann-La Roche Ltd. and Google Inc., may expand the scope of their current analytical software and services to include visualization and exploration functions and features similar to Persephone. We are unable to predict what effect evolution of these industries and potential new entrants may have on price, selling strategies, intellectual property or our competitive position.

Publicly Traded Peers of Cerevel Therapeutics Holdings Inc

Revenue and income for trailing 12 months, in millions of $, except employees
Company Market Cap Revenues Income Employees
Cerevel Therapeutics Holdings Inc 8,165.22 0.00 -460.47 260
Abbvie Inc 463,275.89 64,386.00 6,316.00 57,000
Vertex Pharmaceuticals Inc 133,421.11 12,587.20 4,405.20 405
Hca Healthcare Inc 96,721.47 76,388.00 7,814.00 320,000
Archer daniels midland Co 38,499.30 82,099.00 1,779.00 41,496
Biogen Inc 33,520.59 9,937.40 1,371.90 7,500
SUBTOTAL 1,042,802.13 404,440.65 14,299.42 563,522
108 more competitors available

Sign in to see all competitors of Cerevel Therapeutics Holdings Inc .

Sources: Cerevel Therapeutics Holdings Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Cerevel Therapeutics Holdings Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.

Cerevel Therapeutics Holdings Inc's Competitors Named by the Company

Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.
Competitor Basis Confidence Active Sources
Sage Therapeutics Inc Named by the company 85% 2022 to 2026 3
F.Hoffmann-La Roche Ltd Named by the company 85% 2022 to 2026 3
Advanta India Limited Named by the company 85% 2022 to 2026 3
S&W Seed Company Named by the company 85% 2022 to 2026 3
Multiple Advanced Products Named by the company 85% 2022 to 2026 3
KWS Saat AG Named by the company 85% 2022 to 2026 3
Google Inc Named by the company 85% 2022 to 2026 3
The Dow Chemical Company Named by the company 85% 2022 to 2026 3
Winfield Solutions LLC Named by the company 85% 2022 to 2026 3
Full Agricultural Biotech Seed Company Named by the company 85% 2022 to 2026 3
Syngenta AG Named by the company 85% 2022 to 2026 3
Current Commercial Products Named by the company 85% 2022 to 2026 3
Monsanto Company Named by the company 85% 2022 to 2026 3
Avenue Therapeutics Inc Named by the company 85% 2022 to 2026 3
Abbvie Inc Named by the company 85% 2022 to 2026 3
Karuna Therapeutics Inc Named by the company 85% 2022 to 2026 3
Aptinyx Inc Named by the company 85% 2022 to 2026 3
Praxis Precision Medicines Inc Named by the company 85% 2022 to 2026 3
Intra cellular Therapies Inc Named by the company 85% 2022 to 2026 3
Biogen Inc Named by the company 85% 2022 to 2026 3
Vertex Pharmaceuticals Inc Named by the company 85% 2022 to 2026 3
Theravance Biopharma inc Named by the company 85% 2022 to 2026 3
Competitor Evidence Detail

Filing basis, confidence, active dates and source counts for Cerevel Therapeutics Holdings Inc's named competitors require a Commercial License.

Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.

Cerevel Therapeutics Holdings Inc's Business Segment Mix vs Peers

Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).
Company Largest Segment 2nd Segment 3rd Segment
Vertex Pharmaceuticals Inc Pharmaceuticals 100.00 % - -
Hca Healthcare Inc American Group 34.90 % Atlantic Group 32.91 % National Group 27.95 %
Archer daniels midland Co Ag Services and Oilseeds 76.86 % Carbohydrate Solutions 13.19 % Nutrition 9.42 %
Biogen Inc Reportable 100.00 % - -
Dupont De Nemours Inc Diversified Industrials 52.94 % Healthcare and Water Technologies 47.06 % -

Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).

22 more Peers available

Sign in to see all peers for Cerevel Therapeutics Holdings Inc .

Cerevel Therapeutics Holdings Inc's Productivity vs Peers Comparison

Revenue and income per employee, trailing 12 months, in $; market cap in millions of $
CompanyMarket CapRevenue / EmployeeIncome / Employee
Cerevel Therapeutics Holdings Inc 8,165 0 -1,771,031
Abbvie Inc 463,276 1,129,579 110,807
Vertex Pharmaceuticals Inc 133,421 31,079,506 10,877,037
Hca Healthcare Inc 96,721 238,713 24,419
Archer daniels midland Co 38,499 1,978,480 42,872
Biogen Inc 33,521 1,324,987 182,920
PEERS TOTAL 1,034,637 718,033 26,204
108 more Peers available

Sign in to see all peers for Cerevel Therapeutics Holdings Inc .

Cerevel Therapeutics Holdings Inc's Geographic Revenue Exposure vs Peers

Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.
Company Largest Market 2nd Market 3rd Market
Vertex Pharmaceuticals Inc United States 61.68 % Europe 29.33 % Other Countries Outside of the United States and Europe 8.99 %
Horizon Therapeutics Public Limited Company United States 97.76 % Non Us 2.34 % -
Dupont De Nemours Inc United States 44.47 % Asia Pacific 24.96 % EMEA 22.21 %
Jazz Pharmaceuticals Plc United States 89.79 % Europe 8.64 % Other Countries 1.56 %
Mosaic Co United States 39.43 % Brazil 30.85 % Other Foreign 16.21 %

Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.

4 more Peers available

Sign in to see all peers for Cerevel Therapeutics Holdings Inc .

Cerevel Therapeutics Holdings Inc's Valuation vs Competitive Position

Valuation multiples vs the Major Pharmaceutical Preparations industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.
Metric Company Industry Average Difference
P/E - 25.5x -
EV / EBITDA - 17.3x -
P/B 16.4x 4.5x +11.8x
Return on Equity -98.94 % industry aggregate -108.60 %
Return on Invested Capital -33.53 % -2.97 % (avg) -30.56 %

Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.

Cerevel Therapeutics Holdings Inc's Multi-Year Financial Trajectory

Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.
Metric 201320152020202120222023
Revenue Growth -27.72 %59.82 %-100.00 %---
Operating Margin -838.84 %-797.06 %----
Return on Invested Capital -46.17 %-168.90 %-72.94 %-22.42 %-27.97 %-32.42 %
P/E ------

Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.

Cerevel Therapeutics Holdings Inc's SWOT

Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.

Strengths

No rule matched.

Weaknesses

  • Return on equity 108.6 points below the industry aggregate.
  • Piotroski F-Score of 2 or below, the standard financial-distress signal.

Opportunities

  • A meaningful share of tracked competitors (45.20 %) show financial-distress signals, a possible opening to gain share.

Threats

  • Tracked peer group's revenue run-rate is broadly decelerating (-5.3% annualized).

Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.

Cerevel Therapeutics Holdings Inc's Financial Strength vs Peers Comparison

Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months
CompanyQuick RatioWorking CapitalDebt / EquityAsset Turnover
Cerevel Therapeutics Holdings Inc 3.33 10.31 0.91 -
Abbvie Inc 0.16 0.75 - 0.48
Vertex Pharmaceuticals Inc 1.34 2.85 - 0.48
Hca Healthcare Inc 0.06 0.90 - 1.27
Archer daniels midland Co 0.47 1.36 0.36 1.54
Biogen Inc - 2.74 0.35 0.34
108 more Peers available

Sign in to see all peers for Cerevel Therapeutics Holdings Inc .

Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.

Cerevel Therapeutics Holdings Inc's Revenue and Income Growth vs Peers

Quarterly revenue and net income growth, year over year and quarter over quarter
CompanyPeriodRevenue Y/YRevenue Q/QIncome Y/YIncome Q/Q
Cerevel Therapeutics Holdings Inc Q1 2024----
Abbvie Inc Q2 2026+10.2 %+13.3 %+284.3 %+418.8 %
Vertex Pharmaceuticals IncQ2 2026+12.5 %+11.6 %+6.5 %+6.6 %
Hca Healthcare Inc Q1 2026+4.3 %-2.1 %+1.8 %-14.1 %
Archer daniels midland CoQ2 2026+7.2 %+10.7 %+320.3 %+201.0 %
Biogen Inc Q1 2026+1.9 %+8.7 %+32.8 %-
PEERS TOTAL+7.0 %+11.6 %+112.5 %+780.4 %
108 more Peers available

Sign in to see all peers for Cerevel Therapeutics Holdings Inc .

Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.

Cerevel Therapeutics Holdings Inc's Peers' Costs of Sales and Capital Expenditures

Context for revenue growth: peer costs and capex, year over year and quarter over quarter
CompanyPeriodCosts Y/YCosts Q/QCapex Y/YCapex Q/Q
Cerevel Therapeutics Holdings Inc Q1 2024---19.3 %-70.0 %
Abbvie Inc Q2 2026-1.3 %+1.7 %+19.7 %+21.5 %
Vertex Pharmaceuticals IncQ2 2026+20.0 %+24.5 %-23.0 %-15.9 %
Hca Healthcare Inc Q1 2026--+12.9 %-24.8 %
Archer daniels midland CoQ2 2026+4.8 %+7.7 %-10.8 %+40.2 %
Biogen Inc Q1 2026+5.0 %+33.4 %+8.7 %-15.0 %
108 more Peers available

Sign in to see all peers for Cerevel Therapeutics Holdings Inc .

Cerevel Therapeutics Holdings Inc's Returns and Turnover vs Peers

ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover
CompanyROAROIROEReceivables TurnoverInventory Turnover
Cerevel Therapeutics Holdings Inc -----
Abbvie Inc 4.68%9.11%-4.993.66
Vertex Pharmaceuticals Inc16.88%19.97%23.31%6.191.03
Hca Healthcare Inc 12.94%18.54%-7.09-
Archer daniels midland Co3.33%5.61%7.77%23.967.39
Biogen Inc 4.71%5.23%7.54%6.961.13
108 more Peers available

Sign in to see all peers for Cerevel Therapeutics Holdings Inc .

ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).

Cerevel Therapeutics Holdings Inc's Valuation vs Peers

P/E, price to sales, PEG, price to cash flow and price to book
CompanyP/EPrice / SalesPEGP/CFPrice / Book
Cerevel Therapeutics Holdings Inc ---48.9814.47
Abbvie Inc 73.907.201.484,541.92-
Vertex Pharmaceuticals Inc30.4810.60-113.836.59
Hca Healthcare Inc 14.831.270.52--
Archer daniels midland Co21.760.470.70-1.63
Biogen Inc 24.233.37-45.621.80
PEERS AVERAGE72.932.58119.626.11
108 more Peers available

Sign in to see all peers for Cerevel Therapeutics Holdings Inc .

P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.

Get the full CSIMarket dataset: Subscribe API License